Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 24940873)

1.

Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535.

Gedaly R, Galuppo R, Daily MF, Shah M, Maynard E, Chen C, Zhang X, Esser KA, Cohen DA, Evers BM, Jiang J, Spear BT.

PLoS One. 2014 Jun 18;9(6):e99272. doi: 10.1371/journal.pone.0099272. eCollection 2014.

2.

Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.

Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT, Gedaly R.

Anticancer Res. 2014 Apr;34(4):1709-13.

PMID:
24692700
3.

FH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β-catenin signaling pathway.

Liu J, Li G, Liu D, Liu J.

Mol Med Rep. 2014 Apr;9(4):1289-92. doi: 10.3892/mmr.2014.1928. Epub 2014 Jan 30.

PMID:
24482011
4.

FH535 increases the radiosensitivity and reverses epithelial-to-mesenchymal transition of radioresistant esophageal cancer cell line KYSE-150R.

Su H, Jin X, Zhang X, Zhao L, Lin B, Li L, Fei Z, Shen L, Fang Y, Pan H, Xie C.

J Transl Med. 2015 Mar 31;13(1):104. doi: 10.1186/s12967-015-0464-6.

5.
6.

Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system.

Latasa MU, Salis F, Urtasun R, Garcia-Irigoyen O, Elizalde M, Uriarte I, Santamaria M, Feo F, Pascale RM, Prieto J, Berasain C, Avila MA.

PLoS One. 2012;7(12):e52711. doi: 10.1371/journal.pone.0052711. Epub 2012 Dec 20.

7.

Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.

Yamashita T, Budhu A, Forgues M, Wang XW.

Cancer Res. 2007 Nov 15;67(22):10831-9.

8.

Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells.

Wei W, Chua MS, Grepper S, So SK.

Mol Cancer. 2009 Sep 24;8:76. doi: 10.1186/1476-4598-8-76.

9.

SOX1 functions as a tumor suppressor by antagonizing the WNT/β-catenin signaling pathway in hepatocellular carcinoma.

Tsao CM, Yan MD, Shih YL, Yu PN, Kuo CC, Lin WC, Li HJ, Lin YW.

Hepatology. 2012 Dec;56(6):2277-87. doi: 10.1002/hep.25933.

PMID:
22767186
10.

Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells.

Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, Zhang SH, Huang DD, Tang L, Kong XN, Chen C, Liu SQ, Wu MC, Wang HY.

Cancer Res. 2008 Jun 1;68(11):4287-95. doi: 10.1158/0008-5472.CAN-07-6691.

11.

Dickkopf 4 (DKK4) acts on Wnt/β-catenin pathway by influencing β-catenin in hepatocellular carcinoma.

Fatima S, Lee NP, Tsang FH, Kolligs FT, Ng IO, Poon RT, Fan ST, Luk JM.

Oncogene. 2012 Sep 20;31(38):4233-44. doi: 10.1038/onc.2011.580. Epub 2012 Jan 16.

PMID:
22249261
12.

DIF-1 inhibits the Wnt/β-catenin signaling pathway by inhibiting TCF7L2 expression in colon cancer cell lines.

Jingushi K, Takahashi-Yanaga F, Yoshihara T, Shiraishi F, Watanabe Y, Hirata M, Morimoto S, Sasaguri T.

Biochem Pharmacol. 2012 Jan 1;83(1):47-56. doi: 10.1016/j.bcp.2011.10.001. Epub 2011 Oct 8.

PMID:
22005519
13.
14.

Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.

Wei W, Chua MS, Grepper S, So S.

Int J Cancer. 2010 May 15;126(10):2426-36. doi: 10.1002/ijc.24810.

PMID:
19662654
15.

A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities.

Handeli S, Simon JA.

Mol Cancer Ther. 2008 Mar;7(3):521-9. doi: 10.1158/1535-7163.MCT-07-2063.

16.

Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma.

Kaur P, Mani S, Cros MP, Scoazec JY, Chemin I, Hainaut P, Herceg Z.

Tumour Biol. 2012 Apr;33(2):325-36. doi: 10.1007/s13277-012-0331-5. Epub 2012 Feb 15.

PMID:
22351518
17.

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM.

Clin Cancer Res. 2012 Sep 15;18(18):4997-5007. Epub 2012 Jul 18.

18.

Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells.

Liu J, Ding X, Tang J, Cao Y, Hu P, Zhou F, Shan X, Cai X, Chen Q, Ling N, Zhang B, Bi Y, Chen K, Ren H, Huang A, He TC, Tang N.

PLoS One. 2011;6(11):e27496. doi: 10.1371/journal.pone.0027496. Epub 2011 Nov 15.

19.

Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells.

Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali KC, Atabey N, Ozturk M.

Mol Cancer. 2009 Oct 22;8:90. doi: 10.1186/1476-4598-8-90.

20.

Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.

Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, Cunha AS, Bioulac-Sage P, Perret C.

Oncogene. 2007 Feb 1;26(5):774-80. Epub 2006 Sep 11.

PMID:
16964294
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk